Idexx Laboratories ( (IDXX) ) has released its Q4 earnings. Here is a breakdown of the information Idexx Laboratories presented to its investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, offers diagnostic and software products and services that support veterinary medicine, ensuring safer milk and water globally. The company is a member of the S&P 500 Index and operates in over 175 countries.
In its latest earnings report, IDEXX Laboratories announced a strong performance for the fourth quarter and full year of 2024. The company achieved a 6% increase in revenue for both the quarter and the year, driven by the Companion Animal Group (CAG) and its diagnostics recurring revenue. Earnings per share (EPS) also saw significant growth, with a 13% increase in the fourth quarter.
Key financial highlights include a fourth-quarter revenue of $954 million, a 6% increase, supported by a 7% organic growth in CAG Diagnostics recurring revenue. The company’s EPS for the year was $10.67, reflecting a 6% rise on a reported basis, despite challenges from currency changes and a litigation expense. Notably, IDEXX’s innovations, such as the inVue Dx™ Cellular Analyzer, are set to enhance veterinary care.
Looking ahead, IDEXX Laboratories projects a revenue range of $4,055 million to $4,170 million for 2025, indicating continued growth. The company anticipates EPS to increase by 10% to 15%, emphasizing solid organic revenue gains and improvements in operating margins. IDEXX plans to repurchase approximately $1.5 billion in shares, subject to market conditions.
Overall, IDEXX Laboratories remains confident in sustaining its growth momentum through ongoing innovation and strategic initiatives, as reflected in its forward-looking revenue and earnings projections for 2025.
